Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 3/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31074251 | 0.84 | ADRB1 (0.58) | TRPA1PTGS1CACNA1CADRB1ADRA2A | |
| SCHEMBL23250678 | 0.84 | TRPA1 (0.52) | TRPA1PTGS1CACNA1CADRB1ADRA2A | |
| SCHEMBL20207693 | 0.83 | ADRB1 (0.51) | TRPA1PTGS1CACNA1CADRB1ADRA2A | |
| SCHEMBL20201848 | 0.83 | ADRB1 (0.51) | TRPA1PTGS1CACNA1CADRB1ADRA2A | |
| SCHEMBL16216243 | 0.83 | ADRB1 (0.61) | TRPA1PTGS1CACNA1CADRB1ADRA2A | |
| SCHEMBL16216092 | 0.83 | ADRB1 (0.61) | TRPA1PTGS1CACNA1CADRB1ADRA2A | |
| SCHEMBL3037335 | 0.82 | ALDH1A1 (0.57) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| Hydrochloric Acid SCHEMBL22723284 | 0.81 | ADRB1 (0.50) | TRPA1PTGS1CACNA1CADRB1ADRA2A | |
| Hydrochloric Acid SCHEMBL20188109 | 0.81 | ADRB1 (0.50) | TRPA1PTGS1CACNA1CADRB1ADRA2A | |
| SCHEMBL20376508 | 0.79 | ADRB1 (0.57) | TRPA1PTGS1CACNA1CADRB1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-112679635-B | Preparation method of supported metallocene catalyst and catalyst prepared by preparation method | 中国石油化工股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885PTGS1 2769/4885CACNA1C 3597/4885 |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | TRPA1 3904/4885PTGS1 817/4885CACNA1C 2611/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885PTGS1 2769/4885CACNA1C 3597/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885PTGS1 2769/4885CACNA1C 3597/4885 |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | JAK2, ABL1, FLT3 | TRPA1 2999/4885PTGS1 2024/4885CACNA1C 4324/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | TRPA1 4253/4885PTGS1 1866/4885CACNA1C 4836/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | TRPA1 1899/4885PTGS1 755/4885CACNA1C 2160/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | TRPA1 4870/4885PTGS1 2118/4885CACNA1C 4682/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | TRPA1 3610/4885PTGS1 2569/4885CACNA1C 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.